Aardvark Therapeutics, Inc. Common Stock AARD Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.44M+32.7% | $47.05M+19.8% | $39.29M+51.1% | $26M-1.9% | $26.5M-57.0% | ||
| $28.76M-54.3% | $62.98M-27.7% | $87.07M-24.8% | $115.82M-7.2% | $124.76M+938% | ||
| $93.58M-16.4% | $111.89M-13.4% | $129.21M-10.7% | $144.77M-6.3% | $154.55M+108% | ||
| $98.59M-15.9% | $117.18M-12.0% | $133.23M-9.7% | $147.48M-6.1% | $157.03M+103% | ||
| $4.49M+117% | $2.07M-53.4% | $4.44M-12.1% | $5.06M+97.8% | $2.56M+11.2% | ||
| $11.6M+10.0% | $10.55M-1.8% | $10.74M+4.1% | $10.31M+72.5% | $5.98M+21.3% | ||
| $11.6M+10.0% | $10.55M-2.8% | $10.85M+2.9% | $10.55M+66.5% | $6.34M+17.5% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$137.51M-18.6% | -$115.92M-17.9% | -$98.32M-19.9% | -$82M-21.2% | -$67.64M-16.0% | ||
| $86.99M-18.4% | $106.63M-12.9% | $122.38M-10.6% | $136.93M-9.1% | $150.69M+376% | ||
| $98.59M-15.9% | $117.18M-12.0% | $133.23M-9.7% | $147.48M-6.1% | $157.03M+103% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aardvark Therapeutics, Inc. Common Stock's total assets?
- Aardvark Therapeutics, Inc. Common Stock (AARD) holds $98.6M in total assets, down 37.2% year over year.
- How much debt does Aardvark Therapeutics, Inc. Common Stock have?
- Aardvark Therapeutics, Inc. Common Stock carries $336.0K in total debt against $87.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Aardvark Therapeutics, Inc. Common Stock have?
- Aardvark Therapeutics, Inc. Common Stock holds $62.4M in cash and equivalents.
- Can Aardvark Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 8.06 — current assets exceed current liabilities.
- Where does Aardvark Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.